These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2494640)

  • 41. [Inhaled antibiotic therapy in cystic fibrosis].
    Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
    Ratjen F; Döring G; Nikolaizik WH
    Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients.
    Paull A; Morgan JR
    J Antimicrob Chemother; 1986 Nov; 18(5):635-9. PubMed ID: 3100487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
    Hamed K; Debonnett L
    Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
    Panguluri S; Gunda P; Debonnett L; Hamed K
    Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
    Berlana D; Llop JM; Manresa F; Jódar R
    Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G; Jahnke N; Remmington T
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Azlocillin in cystic fibrosis.
    Malmborg AS; Alfredsson H; Strandvik B
    Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.
    Conway SP; Miller MG; Ramsden C; Littlewood JM
    Acta Paediatr Scand; 1985 Jan; 74(1):107-13. PubMed ID: 3885674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].
    Rognon A; Curti C; Montana M; Terme T; Rathelot P; Vanelle P
    Therapie; 2011; 66(6):481-91. PubMed ID: 22186073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A real world evaluation of the long-term efficacy of strategies to prevent chronic Pseudomonas aeruginosa pulmonary infection in children with cystic fibrosis.
    Mostofian F; Alkadri J; Tang K; Thampi N; Radhakrishnan D
    Int J Infect Dis; 2019 Aug; 85():92-97. PubMed ID: 31132474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.
    Pedersen SS; Jensen T; Osterhammel D; Osterhammel P
    Antimicrob Agents Chemother; 1987 Apr; 31(4):594-9. PubMed ID: 3606063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.